MassBiologics
MassBiologics, part of UMass Chan Medical School, is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States. With over 100 years of experience, it is dedicated to improving public health through the research, development, and production of biologic products, including vaccines and monoclonal antibodies.
Industries
Nr. of Employees
large (251-1000)
MassBiologics
460 Walk Hill Street, Boston, MA 02126
Awards
Navy Multi-Topic 2021 - Advanced Biomedical Product Development in Support of Naval Operations
Oral biologics as novel pre-exposure prophylaxis against all major pathogenic Enterotoxigenic Escherichia coli (ETEC) strains
Funding (ceiling)
$4,718,756
Award Year
2021
Products
Tetanus and Diphtheria (Td) toxoid vaccine (adsorbed)
Licensed vaccine product manufactured and distributed nationwide for routine immunization.
Licensed and investigational monoclonal antibody therapeutics
Portfolio of developed and partnered monoclonal antibody candidates and licensed antibody therapeutics for infectious and other indications; includes products at investigational and commercial stages.
Tetanus and Diphtheria (Td) toxoid vaccine (adsorbed)
Licensed vaccine product manufactured and distributed nationwide for routine immunization.
Licensed and investigational monoclonal antibody therapeutics
Portfolio of developed and partnered monoclonal antibody candidates and licensed antibody therapeutics for infectious and other indications; includes products at investigational and commercial stages.
Expertise Areas
- Clinical trial supply and early-phase clinical support
- Biologics process development
- cGMP biologics manufacturing
- Monoclonal antibody and nanobody discovery
Key Technologies
- Monoclonal antibody production
- Nanobody and secretory IgA therapeutics
- Mammalian cell culture
- Bacterial expression systems
News & Updates
MassBiologics has partnered with SparingVision to manufacture gene therapy aimed at treating ocular diseases.
MassBiologics has entered into an agreement with PTC Therapeutics to manufacture biological investigational new drugs and commercial pharmaceutical products for use in humans.
Victor Ambros, a researcher at UMass Chan Medical School, was awarded the 2024 Nobel Prize for his discovery of microRNA, which plays a crucial role in gene regulation.
PTC Therapeutics announced that the European Commission has granted marketing authorization for Upstaza, a gene therapy developed in partnership with MassBiologics.
MassBiologics has partnered with SparingVision to manufacture gene therapy aimed at treating ocular diseases.
MassBiologics has entered into an agreement with PTC Therapeutics to manufacture biological investigational new drugs and commercial pharmaceutical products for use in humans.
Victor Ambros, a researcher at UMass Chan Medical School, was awarded the 2024 Nobel Prize for his discovery of microRNA, which plays a crucial role in gene regulation.
PTC Therapeutics announced that the European Commission has granted marketing authorization for Upstaza, a gene therapy developed in partnership with MassBiologics.